Aaron L. Dane

Liverpool, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Considerations in Designing Clinical Trials of Novel Antibacterial Agents Using a Superiority Design.

Considerations in Designing Clinical Trials of Novel Antibacterial Agents Using a Superiority Design.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 02, 2026

Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study.

Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study.

Journal: The Journal of antimicrobial chemotherapy

Published: November 24, 2025

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.

Journal: The Lancet. Infectious diseases

Published: February 17, 2025

Long-term safety of dexamethasone sodium phosphate encapsulated in autologous erythrocytes in pediatric patients with ataxia telangiectasia.

Long-term safety of dexamethasone sodium phosphate encapsulated in autologous erythrocytes in pediatric patients with ataxia telangiectasia.

Journal: Frontiers in neurology

Published: November 12, 2024

Exeporfinium chloride (XF-73) nasal gel significantly reduces Staphylococcus aureus nasal carriage in cardiac surgery patients throughout surgery and the early recovery period: results from a randomized placebo-controlled Phase 2 study.

Exeporfinium chloride (XF-73) nasal gel significantly reduces Staphylococcus aureus nasal carriage in cardiac surgery patients throughout surgery and the early recovery period: results from a randomized placebo-controlled Phase 2 study.

Journal: Infection control and hospital epidemiology

Published: October 10, 2024

Cefepime-Taniborbactam in Complicated Urinary Tract Infection.

Cefepime-Taniborbactam in Complicated Urinary Tract Infection.

Journal: The New England journal of medicine

Published: February 14, 2024

Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study.

Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study.

Journal: Infection control and hospital epidemiology

Published: March 23, 2023

Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need.

Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: December 30, 2022

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.

Journal: The New England journal of medicine

Published: April 07, 2022

The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare Pathogens.

The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare Pathogens.

Journal: Open forum infectious diseases

Published: March 02, 2022

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections.

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections.

Journal: Antimicrobial agents and chemotherapy

Published: September 07, 2021

An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.

An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.

Journal: The Journal of antimicrobial chemotherapy

Published: July 05, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026